This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 6850766 results found since Jan 2013.
New Data from KEYNOTE-028, Merck ’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Dateline City:
KENILWORTH, N.J. Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new findings from the KEYNOTE-028 Phase 1b study, the
clinical trial investigating the use of the company ’s anti-PD-1 therapy,
KEYTRUDA ® (pembrolizumab) in multiple, difficult-to-treat
cancers. Data from this trial, to be presented at the European Cancer
Congress (ECC) in Vienna, Austria, Sept. Language:
English Contact: Merc...
Source: Merck.com - Product News - September 27, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
New Findings Show Anti-Tumor Activity of KEYTRUDA ® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
Dateline City:
KENILWORTH, N.J. KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients Results from KEYNOTE-028 Presented at 2015 European Cancer Congress KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1
therapy, as a monotherapy in patients with advanced unresectable
nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose
...
Source: Merck.com - Product News - September 26, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Data in Nine Difficult-to-Treat Cancers from Merck ’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Dateline City:
KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new data investigating the anti-tumor activity of
KEYTRUDA ® (pembrolizumab) across a broad range of advanced
cancers will be presented at this year ’s European Cancer Congress (ECC)
in ...
Source: Merck.com - Product News - September 21, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck and Samsung Bioepis Announce Approval of BRENZYS ™ (Etanercept), a Biosimilar of Enbrel, in Korea
Dateline City:
KENILWORTH, N.J. & SEOUL, South Korea First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide KENILWORTH, N.J. & SEOUL, South Korea--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS ™
(etanercept), a biosimilar of the immunology medicine Enbrel, by the
Ministry of Food and Drug Safety (MFDS) in Korea. Language:
English Contact: Merck Media: Pamela Eisele, 267-3...
Source: Merck.com - Product News - September 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Results of Phase 2 Study of Merck ’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Dateline City:
KENILWORTH, N.J. Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that a Phase 2 study of relebactam, the company ’s
investigational beta-lactamase inhibitor, in combination with
imipenem/cilastatin (an approved carbapenem antibiotic), in patients
with complicated urinary tract infections, met its primary endpoint. Language:
English Contact: Merck Media: Pamela Eisele, (267) 305-3558 or Robert Con...
Source: Merck.com - Research and Development News - June 20, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASM MSD NYSE:MRK Source Type: news
Merck ’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City:
KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced results from two Phase 3 studies evaluating MK-1293,
Merck ’s investigational, follow-on biologic* insulin glargine candidate
for the treatment of people with type 1 and type 2 diabetes. Language:
English Contact: Merck Media: Doris Li, 908-246-5701 Kristen Dra...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
KEYTRUDA ® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
Dateline City:
KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings from
KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA ® (pembrolizumab),
the company ’s anti-PD-1 therapy, as a monotherapy in patients with
relapsed or refractory classical Hodgkin lymphoma (cHL). These data will
be presented...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news
Updated Findings from KEYNOTE-012 for KEYTRUDA ® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
Dateline City:
KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new data with KEYTRUDA ® (pembrolizumab), the
company ’s anti-PD-1 therapy, as a monotherapy from two studies
(KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Data are being presented at the 52 nd Annual Me...
Source: Merck.com - Research and Development News - June 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news
New Data from Phase 2 Study Evaluating KEYTRUDA ® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Dateline City:
KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced updated findings from a study evaluating KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
advanced cancers characterized as deficient for DNA mismatch repair
(MMR). Language:
English Contact: Merck Media: Pamela Eisele, 267-305-3558 Kim Hamilton, 908-740-1863 or Investors: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news
New Data for KEYTRUDA ® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three separate studies evaluating the use
of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1
therapy, in combination with other treatment regimens including
talimogene laherparepvec, dabrafenib plus trametinib, or low-dose
ipilimumab in patients with advanced melanoma. Language:
English Contact: Merck Media Contacts: Pamela Eisele, 267-305-3558 or An Phan, 908-255-6325 or Investor Contacts: Te...
Source: Merck.com - Research and Development News - June 5, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced new data, including updated response rates,
progression-free survival (PFS) and overall survival (OS) with KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news
New Data Evaluating KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Dateline City:
KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced findings from an initial proof-of-concept study of
KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy,
combined with standard treatments, one with bevacizumab and others
without, in non-small cell lung cancer (NSCLC) including chemotherapy in
previously untreated patients with NSCLC; the study showed overall
...
Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news
New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J. Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced final overall survival (OS) data from KEYNOTE-006 and
new findin...
Source: Merck.com - Research and Development News - May 18, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
New KEYTRUDA ® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
Dateline City:
KENILWORTH, N.J. Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new and updated data investigating KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy, in more than 15 types
of cancer will be presented at the 52 nd Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, June 3 – 7,
2016. Language:
...
Source: Merck.com - Research and Development News - May 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news
Merck to Present New Data for KEYTRUDA ® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Dateline City:
KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new research investigating the use of KEYTRUDA ®
(pembrolizumab), the company ’s anti-PD-1 therapy, in multiple tumor
types, both as a single agent and in combination with other therapies,
will be presented at this year’s American Association for Cancer
Research (AACR) Annual Meeting in New Orleans, Apri...
Source: Merck.com - Research and Development News - April 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK AACR Keytruda NYSE:MRK Source Type: news
